Bottom line
How much do PHSYX and VGHCX overlap?
59% of their top holdings overlap by weight. 14 securities appear in both funds' top 25, making up 63.1% of PHSYX's assets and 45.4% of VGHCX's. They share a meaningful core but differ in the rest of the portfolio.
Updated Nov 22, 2026
Overlap at a glance
Holdings PHSYX and VGHCX have in common
| Holding | % of PHSYX | % of VGHCX | Overlap |
|---|---|---|---|
| Eli Lilly & Co. | 13.15% | 8.61% | 8.61% |
| Johnson & Johnson | 8.46% | 4.83% | 4.83% |
| UnitedHealth Group, Inc. | 6.93% | 4.05% | 4.05% |
| AbbVie, Inc. | 6.05% | 2.30% | 2.30% |
| Merck & Co., Inc. | 4.88% | 5.44% | 4.88% |
| AstraZeneca plc | 4.67% | 4.59% | 4.59% |
| Intuitive Surgical, Inc. | 4.04% | 2.52% | 2.52% |
| Edwards Lifesciences Corp. | 2.80% | 2.56% | 2.56% |
| Roche Holding AG | 2.79% | 1.18% | 1.18% |
| CVS Health Corp. | 2.74% | 2.52% | 2.52% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 2.36% | 1.97% |
| Boston Scientific Corp. | 1.80% | 1.53% | 1.53% |
| Dexcom, Inc. | 1.64% | 1.18% | 1.18% |
| HCA Healthcare, Inc. | 1.18% | 1.68% | 1.18% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PHSYX
- Novartis AG — 5.13%
- Thermo Fisher Scientific, Inc. — 4.50%
- Sanofi SA — 3.23%
- Gilead Sciences, Inc. — 2.63%
- McKesson Corp. — 2.14%
- Cardinal Health, Inc. — 2.12%
- Novo Nordisk A/S — 1.90%
- Bristol-Myers Squibb Co. — 1.75%
- Hoya Corp. — 1.52%
- Putnam Short Term Investment Fund — 1.35%
- Amgen, Inc. — 1.11%
Only in VGHCX
- Gsk Plc — 3.00%
- Cencora Inc — 2.47%
- Danaher Corp — 2.18%
- Regeneron Pharmaceuticals Inc — 2.14%
- Novartis AG — 1.91%
- Elevance Health Inc — 1.83%
- Argenx SE — 1.68%
- Ucb Sa — 1.67%
- Agilent Technologies Inc — 1.49%
- Biogen Inc — 1.46%
- Galderma Group AG — 1.37%
Asset mix
| Asset type | PHSYX | VGHCX |
|---|---|---|
| Stocks | 98.2% | 97.6% |
| Repurchase agreements | — | 2.2% |
| Other | 1.4% | — |
| Cash & short-term funds | 0.6% | 0.1% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Country mix
| Country | PHSYX | VGHCX |
|---|---|---|
| US | 76.2% | 77.6% |
| CH | 7.9% | 4.5% |
| GB | 6.4% | 7.6% |
| JP | 2.4% | 4.8% |
| BE | — | 3.4% |
| FR | 3.2% | — |
| DK | 2.4% | 1.4% |
| NL | 1.2% | — |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do PHSYX and VGHCX overlap?
What stocks do PHSYX and VGHCX have in common?
Should I own both PHSYX and VGHCX?
Which holds more stocks, PHSYX or VGHCX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.